Victoria L.M. Herrera, MD
Professor
Boston University School of Medicine
Dept of Medicine
Cardiovascular Medicine

MD, University Philippines




Victoria Herrera, MD, is a Professor of Medicine at Boston University School of Medicine, Whitaker Cardiovascular Institute, Associate Director for Medicine at BU Nanotechnology Innovation Center. Dr. Herrera is a graduate of the University of the Philippines College of Medicine - magna cum laude, and former Visiting International Fellow at Harvard University Graduate School of Arts and Sciences. She completed Pediatrics Residencey at Univerfity of Massachusetts Medical Center and Boston Children's Hospital, Harvard Medical School; Fellowship in Pediatric Cardiology and Molecular Cardiology at Boston Children's Hospital, Harvard Medical School, and Hypertension Molecular Genetics at Boston University School of Medicine. Dr. Herrera serves as reviewer for Journals and for the NIH: former CVB Cardiovascular Study Section member, Hypertension Study Section, and current ad hoc reviewer for Cancer BioTherapeutics and Development SBIR Study Section. Dr. Herrera is co-inventor in multiple patents on novel targeted therapies for cancer and stroke, and nanodelivery systems.

As an NIH physician scientist awardee, research interests focus on the understanding of molecular bases of complex diseases via translational research coupled with animal modeling that recapitulate complex disease phenotypes respectively with spontaneous progression to end-organ disease and comorbidities. These animal modeling insights provide novel approaches to identification and testing of novel therapeutic and/or theranostic paradigms prioritized for their respective potentials to become clinically relevant game changers. Research expertise span the integration of basic and clinical sciences, translation of nanotechnologies into nanomedicines, and the design of clinically relevant preclinical and translational efficacy and safety studies relevant to novel approaches for ARDS, Covid19-ARDS, stroke, cardiovascular disease and cancer.

A graduate of the University of the Philippines College of Medicine, Dr. Herrera served as the founding scientific advisor to the Philippine General Hospital Child Protection Unity and the Child Protection Network in the Philippines.

Member
Boston University
Whitaker Cardiovascular Institute


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences




Multi-functional targeted bio-conjugate platform to dismantle neutrophil extracellular traps (NETs)
01/01/2019 - 12/31/2020 (Multi-PI)
PI: Victoria L.M. Herrera, MD
NIH/National Heart, Lung, and Blood Institute
1R21HL144253-01

Humanized anti-DEspR antibody therapy for Acute Respiratory Distress Syndrome (ARDS)
09/01/2019 - 07/31/2020 (Subcontract Co-PI)
The Brigham and Women's Hospital, Inc. NIH NHLBI
5U54HL119145-07

Fully humanized anti-DEspR antibody therapy for acute lung injury (ALI)/Acute Respiratory Distress Syndrome (ARDS)
01/01/2018 - 04/30/2019 (Subcontract Co-PI)
The Brigham and Women's Hospital, Inc. NIH NHLBI
5U54HL119145-06

Decreasing stroke risk by restoring microvascular repair
02/01/2015 - 01/31/2017 (PI)
Ellison Foundation


Juvenile Protective Factor Deficits in Endothelial Aging, Dysfunction and Disease: Role in Cardio- and Cerebro- Vascular Diseases
08/15/2008 - 05/31/2013 (PI)
NIH/National Institute on Aging
5R01AG032649-04

Juvenile Protective Factor Deficits in Endothelial Aging, Dysfunction and Disease: Role in Cardio- and Cerebro- Vascular Diseases
09/30/2009 - 08/31/2011 (PI)
NIH/National Institute on Aging
3R01AG032649-02S1

Environmental Toxicants: Fetal Basis, Adult-Onset Stroke
01/01/2006 - 12/31/2008 (PI)
NIH/National Institute of Environmental Health Sciences
5 R21 ES13870 02

Integrated Molecular Analysis of Nicotine-Hypertension-Hyperlipidemia Interaction in CHD
03/01/2002 - 04/30/2006 (PI)
Philip Morris Inc

Molecular Genetics of the ET-1/AngII Receptor
04/01/2002 - 03/31/2006 (Co-PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL69937 02

Hypertension/Atherosclerosis Paradigms
08/15/1999 - 07/31/2004 (PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL62857 04

Showing 10 of 13 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2020 Multi-functional targeted bio-conjugate platform to dismantle neutrophil extracellular traps (NETs) 5R21HL144253-02
2019 Multi-functional targeted bio-conjugate platform to dismantle neutrophil extracellular traps (NETs) 1R21HL144253-01
2018 Novel targeted therapy for pancreatic cancer 1R43CA221555-01A1
2011 Juvenile Protective Factor Deficits in Endothelial Aging, Dysfunction and Disease 5R01AG032649-04 4
2010 Juvenile Protective Factor Deficits in Endothelial Aging, Dysfunction and Disease 5R01AG032649-03 4
2009 Juvenile Protective Factor Deficits in Endothelial Aging, Dysfunction and Disease 3R01AG032649-02S1 4
2009 Juvenile Protective Factor Deficits in Endothelial Aging, Dysfunction and Disease 5R01AG032649-02 4
2008 Juvenile Protective Factor Deficits in Endothelial Aging, Dysfunction and Disease 1R01AG032649-01 4
2007 Environmental Toxicants in Fetal Basis of Adult-onset Stroke 5R21ES013870-02 1
2006 Environmental Toxicants: Fetal Basis, Adult-onset Stroke 1R21ES013870-01A1 1
Showing 10 of 28 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Herrera VL, Colby AH, Ruiz-Opazo N, Coleman DG, Grinstaff MW. Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells. Nanomedicine (Lond). 2018 08; 13(16):2083-2098.View Related Profiles. PMID: 30204054
     
  2. Colby AH, Oberlies NH, Pearce CJ, Herrera VL, Colson YL, Grinstaff MW. Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 May; 9(3).View Related Profiles. PMID: 28185434; DOI: 10.1002/wnan.1451;
     
  3. Colby AH, Berry SM, Moran AM, Pasion KA, Liu R, Colson YL, Ruiz-Opazo N, Grinstaff MW, Herrera VL. Highly Specific and Sensitive Fluorescent Nanoprobes for Image-Guided Resection of Sub-Millimeter Peritoneal Tumors. ACS Nano. 2017 02 28; 11(2):1466-1477.View Related Profiles. PMID: 28099801; DOI: 10.1021/acsnano.6b06777;
     
  4. Colby AH, Oberlies NH, Pearce CJ, Herrera V, Colson YL, Grinstaff M. Cover Image, Volume 9, Issue 3. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 2017; 9(3):e1474. View Publication
  5. Colby AH, Oberlies NH, Pearce C, Herrera V, Colson YL, Grinstaff M. Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle: Nanoparticle drug-delivery systems for peritoneal cancers. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 2017; 9(3):e1451. View Publication
  6. Matsuura S, Patterson S, Lucero H, Leiva O, Grant AK, Herrera VL, Ravid K. In vivo magnetic resonance imaging of a mouse model of myelofibrosis. Blood Cancer J. 2016 11 11; 6(11):e497.View Related Profiles. PMID: 27834941; DOI: 10.1038/bcj.2016.97;
     
  7. Herrera VL, Steffen M, Moran AM, Tan GA, Pasion KA, Rivera K, Pappin DJ, Ruiz-Opazo N. Confirmation of translatability and functionality certifies the dual endothelin1/VEGFsp receptor (DEspR) protein. BMC Mol Biol. 2016 Jun 14; 17(1):15.View Related Profiles. PMID: 27301377; PMCID: PMC4906906; DOI: 10.1186/s12867-016-0066-8;
     
  8. Herrera VL, Colby AH, Tan GA, Moran AM, O'Brien MJ, Colson YL, Ruiz-Opazo N, Grinstaff MW. Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis. Nanomedicine (Lond). 2016 May; 11(9):1001-15.View Related Profiles. PMID: 27078118; PMCID: PMC4910944; DOI: 10.2217/nnm-2015-0023;
     
  9. Decano JL, Pasion KA, Black N, Giordano NJ, Herrera VL, Ruiz-Opazo N. Sex-specific genetic determinants for arterial stiffness in Dahl salt-sensitive hypertensive rats. BMC Genet. 2016; 17:19.View Related Profiles. PMID: 26754450; PMCID: PMC4709875; DOI: 10.1186/s12863-015-0324-7;
     
  10. Falde EJ, Freedman JD, Herrera VL, Yohe ST, Colson YL, Grinstaff MW. Layered superhydrophobic meshes for controlled drug release. J Control Release. 2015 Sep 28; 214:23-9.View Related Profiles. PMID: 26160309; PMCID: PMC4841832; DOI: 10.1016/j.jconrel.2015.06.042;
     
Showing 10 of 93 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 93 publications over 30 distinct years, with a maximum of 6 publications in 1994 and 2007 and 2013

YearPublications
19872
19882
19902
19911
19921
19931
19946
19951
19961
19973
19985
19991
20015
20022
20033
20044
20054
20064
20076
20083
20094
20105
20114
20124
20136
20142
20152
20164
20174
20181

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

angiogenesis
transgenic rat models
ultrasound gene transfer
ultrasound molecular imaging
Contact for Mentoring:

700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Google Map


Herrera's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department